Nitrate Modulates Cognitive Impairment Via Oral Microbiota.

Sponsor
Peking University Sixth Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05963659
Collaborator
(none)
70
2
36

Study Details

Study Description

Brief Summary

Alcohol use is increasingly prevalent in modern society and is known to cause cognitive impairment and dysregulation of inflammatory responses. In the present study, the investigators want to perform a randomised controlled trials to test whether nitrate could change the oral microbiota and benefit the cognitive impairment in alcohol dependence patients. The investigators survey the oral bacterial communities in saliva samples of 70 alcohol dependent patients following 14 days of dietary inorganic nitrate (nitrate-rich beetroot juice, ~750 mg NO3- /d) and placebo (nitrate-depleted beetroot juice, ~1 mg NO3- /d) supplementation.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: nitrate-rich beetroot juice
  • Dietary Supplement: nitrate-depleted beetroot juice
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
The Effect of Nitrate on Cognitive Function in Alcohol Dependence Patients and the Potential Microbiota Mechanism.
Anticipated Study Start Date :
Aug 7, 2023
Anticipated Primary Completion Date :
Oct 30, 2023
Anticipated Study Completion Date :
Aug 7, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group N

Dietary Supplement: nitrate-rich beetroot juice
nitrate-rich beetroot juice, ~750 mg NO3- /d

Placebo Comparator: Group P

Dietary Supplement: nitrate-depleted beetroot juice
nitrate-depleted beetroot juice, ~1 mg NO3- /d

Outcome Measures

Primary Outcome Measures

  1. Changes of cognitive function from baseline to post-intervention [baseline and post-intervention(two weeks after baseline test)]

    Test by Cambridge Neuropsychological Test Automatic Battery,CANTAB

  2. Changes of oral microbiota from baseline to post-intervention [baseline and post-intervention(two weeks after baseline test)]

    Saliva samples were used to test the composition of microbiota by 16S RNA sequencing.

  3. Changes of gut microbiota from baseline to post-intervention [baseline and post-intervention(two weeks after baseline test)]

    Feces samples were used to test the composition of microbiota by 16S RNA sequencing.

  4. Changes of nitrate and nitrite levels in serum from baseline to post-intervention [baseline and post-intervention(two weeks after baseline test)]

    The collected serum samples were used to test the levels of nitrate and nitrite by High Performance Liquid Chromatography \ HPLC

Secondary Outcome Measures

  1. Cytokine Interleukin-1b in serum [baseline and post-intervention(two weeks after baseline test)]

    The collected serum samples were used to test the levels of IL-1b by Enzyme-Linked Immunosorbent Assay

  2. Cytokine Interleukin-6 in serum [baseline and post-intervention (two weeks after baseline test)]

    The collected serum samples were used to test the levels of IL-6 by Enzyme-Linked Immunosorbent Assay

  3. Cytokine Interleukin-10 in serum [baseline and post-intervention (two weeks after baseline test)]

    The collected serum samples were used to test the levels of IL-10 by Enzyme-Linked Immunosorbent Assay

  4. Cytokine Tumor Necrosis Factor-a in serum [baseline and post-intervention(two weeks after baseline test)]

    The collected serum samples were used to test the levels of TNF-a by Enzyme-Linked Immunosorbent Assay

  5. The blood biochemical related parameters includes liver enzymes (alanine aminotransferase and aspartate aminotransferase) [baseline and post-intervention (two weeks after baseline test)]

    The collected venous blood were sent to the department of clinical laboratory and the investigators recorded the laboratory report.

  6. The blood biochemical related parameters blood fat (cholesterol, triglycerides, low density lipoprotein and high density lipoprotein [baseline and post-intervention (two weeks after baseline test)]

    The collected venous blood were sent to the department of clinical laboratory and the investigators recorded the laboratory report.

  7. Alcohol craving by Visual Analogue Scale(VAS) [baseline and post-intervention (two weeks after baseline test)]

    Tested by Visual Analogue Scale(VAS)

  8. Alcohol craving [baseline and post-intervention (two weeks after baseline test)]

    Tested by Tested by Penn Alcohol Craving Scale(PACS)

  9. Alcohol withdrawal assessment [baseline and post-intervention (two weeks after baseline test)]

    Tested by Clinical Institute Withdrawal Assessment of Alcohol, revised(CIWA-AR)

  10. Alcohol craving by Alcohol Urge Questionnaire [baseline and post-intervention (two weeks after baseline test)]

    Tested by Alcohol Urge Questionnaire

  11. depression [baseline and post-intervention (two weeks after baseline test)]

    Test by Hamilton Depression Rating Scale

  12. anxiety [baseline and post-intervention(two weeks after baseline test)]

    Test by Hamilton Anxiety Rating Scale

  13. Sleep Quality [baseline and post-intervention (two weeks after baseline test)]

    Test by pittsburgh sleep quality index

  14. blood pressure [baseline and post-intervention (two weeks after baseline test)]

    Test by blood pressure monitor

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Han nationality

  2. Montreal Cognitive Assessment(MoCA) score >11

  3. Diagnosis of alcohol dependence

Exclusion Criteria:
  1. Past or current infectious disease

  2. Past or current heart, brain, liver, kidney, and other severe diseases

  3. Past or current metabolic diseases that can lead to abnormalities of the immune system, such as obesity (Body Mass Index > 30 kg/m2), diabetes, or rheumatoid arthritis

  4. Past or current neurodegenerative diseases, such as Parkinson's disease

  5. Use of steroidal and non-steroidal anti-inflammatory drugs, antibiotics, antioxidants, and immunosuppressive agents within two months of enrollment

  6. Use of probiotics and probiotics every day for the first two months before enrollment

  7. Previous or current DSM-IV diagnosis of schizophrenia, depression, anxiety disorder, bipolar disorder, mental retardation, dementia (excluding mild cognitive impairment, MCI), or substance dependence other than alcohol and nicotine

  8. Irregular eating habits that affect the oral flora (except alcohol) in the previous two months

  9. Current oral disease

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Peking University Sixth Hospital

Investigators

  • Principal Investigator: Hongqiang Sun, Peking University Sixth Hospital
  • Study Chair: Liangjun Pang, Anhui mental health central

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hongqiang Sun, Clinical Professor,Director, Peking University Sixth Hospital
ClinicalTrials.gov Identifier:
NCT05963659
Other Study ID Numbers:
  • 20230630
First Posted:
Jul 27, 2023
Last Update Posted:
Jul 27, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hongqiang Sun, Clinical Professor,Director, Peking University Sixth Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2023